US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Research & Development: market research reports

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

RSS Feeds

Research & Development market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
Vaccines: The End of Illness Overview
4/10/2014 | published by: CHI Insight Pharma Reports
... efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing ...  |  read more...
$2,495.00
Global Hypertension Drugs Market 2014-2018
4/4/2014 | published by: Infiniti Research Limited - TechNavio
... Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There ...  |  read more...
$2,500.00
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
4/1/2014 | published by: FirstWord
... represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the pipeline – led by Gilead, AbbVie and Bristol-Myers Squibb – the battle to transform ...  |  read more...
$4,995.00
Research and Development in Turkey: ISIC 73
3/28/2014 | published by: Euromonitor International
... Research and Development market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis ...  |  read more...
$600.00
Proteins in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 661 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 186 drugs. Proteins In Oncology Drug Pipeline Update lists ...  |  read more...
$5,622.50
Renal Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets. There are today ...  |  read more...
$5,622.50
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... in 1960 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 250 drugs. Tnf-Alpha Signaling Pathway In Oncology Drug ...  |  read more...
$5,622.50
Notch Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... are today 249 companies plus partners developing 343 Notch pathway targeting drugs in 1214 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
$5,622.50
Orphan Drugs in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to ...  |  read more...
$5,622.50
Peptides in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... number of ceased drugs over the last years amount to another 127 drugs. Peptides In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ...  |  read more...
$5,622.50
Oncology Drug Pathway Analyzer (Premium Version)
3/25/2014 | published by: BioSeeker Group AB
... their pathways are the critical link between drugs and their role in the treatment of cancer. This highly unique interactive tool is based on BioSeeker’s linking of hundreds of drug targets in many different types ...  |  read more...
$37,125.00
Prostate Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy ...  |  read more...
$5,622.50
Analytical Tool - Melanoma
3/25/2014 | published by: BioSeeker Group AB
... time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current ...  |  read more...
$11,625.00
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 366 Alpha6Beta4 integrin pathway targeting drugs in 1258 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 164 drugs. ...  |  read more...
$5,622.50
Angiogenesis in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... number of ceased drugs over the last years amount to another 173 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ...  |  read more...
$5,622.50
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 214 companies plus ...  |  read more...
$5,622.50
Brain Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ...  |  read more...
$5,622.50
Cytokine Therapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 7 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
$3,747.50
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 304 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
$5,622.50
FSH Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity ...  |  read more...
$5,622.50
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... drugs in 1260 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 146 drugs. Il-2 Signaling Pathway In Oncology ...  |  read more...
$5,622.50
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 642 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 64 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
$5,622.50
Leukemia Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 126 drugs. Leukemia Drug Pipeline Update lists all drugs and gives ...  |  read more...
$5,622.50
Lung Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe ...  |  read more...
$5,622.50
Lymphoma Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 107 drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you ...  |  read more...
$5,622.50
< prev 1    3  4  5  6  7  8  9  10  
 
Our Clients